For millions of older Americans managing chronic conditions, the decision to skip or ration a prescription due to cost is not a minor inconvenience — it is a documented driver of hospitalizations, disease progression, and preventable mortality. New quasi-experimental evidence now quantifies whether landmark Medicare drug pricing reforms translated into measurable behavioral change at the pharmacy counter.
Using a difference-in-differences design applied to four years of National Health Interview Survey data (2021–2024), investigators compared cost-related medication nonadherence among Medicare Part D enrollees aged 62–67 against a comparator group on private insurance, before and after the Inflation Reduction Act's 2024 provisions took effect. The key reforms analyzed were the elimination of a 5% catastrophic-phase coinsurance requirement — which effectively capped annual out-of-pocket drug spending at roughly $3,300 — and an expansion of full low-income subsidy eligibility. Notably, individuals already protected by prior insulin cost caps, dual Medicaid enrollment, or low-income subsidies were excluded from the primary analysis to isolate the incremental effect of the new provisions on a previously less-protected population.
This study sits within a well-established evidence base linking financial barriers to adherence failures, but it is among the first to use a rigorous quasi-experimental framework to assess the IRA's real-world behavioral impact rather than projecting effects from actuarial models. The difference-in-differences approach strengthens causal inference compared to simple pre-post comparisons, though the 62–67 age band is a narrow slice of Medicare's full population, and the survey's self-reported nature introduces recall bias. The observation window captures only the first year post-implementation — insufficient to evaluate whether adherence gains persist or whether downstream health outcomes, such as reduced hospitalizations or improved disease biomarkers, follow. Still, if confirmed by longer follow-up, the findings suggest that structural out-of-pocket caps may be a more efficient adherence intervention than patient education programs alone — a meaningful signal for health economists and clinicians alike.